1. Volume 146, Issue 6, Pages 1531-1542 (December 2014)
One-Year Safety and Efficacy Study of Arformoterol Tartrate in Patients With Moderate to Severe COPD 
James F. Donohue, MD, FCCP, Nicola A. Hanania, MD, FCCP, Barry Make, MD, FCCP, Matthew C. Miles, MD, Donald A. Mahler, MD, Lisa Curry, BS, Robert Tosiello, MS, Alistair Wheeler, MD, Donald P. Tashkin, MD 
CHEST 
Volume 146, Issue 6, Pages (December 2014)
DOI: /chest
Copyright © 2014 The American College of Chest Physicians Terms and Conditions

2. Figure 1
Consolidated Standards of Reporting Trials (CONSORT) diagram. ITT = intent to treat.
CHEST  , DOI: ( /chest )
Copyright © 2014 The American College of Chest Physicians Terms and Conditions

3. Figure 2 Study design. ARF15BID = arformoterol tartrate 15 μg bid.
CHEST  , DOI: ( /chest )
Copyright © 2014 The American College of Chest Physicians Terms and Conditions

4. Figure 3
Kaplan-Meier plot of the cumulative probability of events for time to respiratory death or first COPD exacerbation-related hospitalization (ITT population). See Figure 1 and 2legends for expansion of abbreviations.
CHEST  , DOI: ( /chest )
Copyright © 2014 The American College of Chest Physicians Terms and Conditions

5. Figure 4
Primary and sensitivity analyses for time-to-first-event analysis: hazard ratio and 90% repeated CI (ITT population). Hazard ratios are indicated by ×; × represents the bounds of the CIs. IPD = important protocol deviation. See Figure 1 and 2legends for expansion of other abbreviations.
CHEST  , DOI: ( /chest )
Copyright © 2014 The American College of Chest Physicians Terms and Conditions